NASDAQ · IBRX
Healthcare · Biotechnology
$8.05
Down-$0.15 (-1.92%)
Updated Aug 31, 2026, 6:54 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IBRX closed at $8.05 after 20 trading sessions, up 12.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $8.31 | $8.3199 | $7.945 | $8.05 | 7.98M |
| Aug 27, 2026 | $8.24 | $8.76 | $8.18 | $8.40 | 12.31M |
| Aug 26, 2026 | $8.17 | $8.40 | $8.07 | $8.25 | 9.45M |
| Aug 25, 2026 | $7.69 | $8.23 | $7.68 | $8.19 | 11.55M |
| Aug 24, 2026 | $7.68 | $7.72 | $7.46 | $7.58 | 5.67M |
| Aug 21, 2026 | $7.85 | $7.95 | $7.60 | $7.79 | 7.62M |
| Aug 20, 2026 | $7.90 | $8.00 | $7.74 | $7.84 | 8.1M |
| Aug 19, 2026 | $8.08 | $8.27 | $7.94 | $8.13 | 13.06M |
| Aug 18, 2026 | $7.785 | $7.83 | $7.54 | $7.72 | 5.41M |
| Aug 17, 2026 | $7.55 | $7.95 | $7.44 | $7.92 | 6.82M |
| Aug 14, 2026 | $7.59 | $7.59 | $7.4301 | $7.57 | 4.91M |
| Aug 13, 2026 | $7.80 | $7.955 | $7.59 | $7.65 | 6.01M |
| Aug 12, 2026 | $7.71 | $7.82 | $7.60 | $7.74 | 5.34M |
| Aug 11, 2026 | $7.54 | $7.66 | $7.48 | $7.60 | 5.03M |
| Aug 10, 2026 | $7.51 | $7.70 | $7.42 | $7.49 | 6M |
| Aug 7, 2026 | $7.40 | $7.65 | $7.25 | $7.64 | 9.39M |
| Aug 6, 2026 | $7.24 | $7.49 | $7.185 | $7.32 | 7.79M |
| Aug 5, 2026 | $6.96 | $7.41 | $6.94 | $7.25 | 11.51M |
| Aug 4, 2026 | $6.76 | $7.26 | $6.70 | $6.95 | 19.01M |
| Aug 3, 2026 | $7.18 | $7.415 | $7.10 | $7.15 | 8.76M |
The latest Smart Investors Daily articles mentioning IBRX.
IBRX research
Company profile and research snapshot.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2026 | BTIG | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
| Apr 21, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 21, 2026
AI and semiconductor volatility gave way to an August recovery as a leveraged hedge fund unwind cleared, and Super Micro and Palantir led BUZZ Index gains. Read more here.
Benzinga · Aug 4, 2026
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Benzinga · Jul 30, 2026
ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.
Benzinga · Jul 30, 2026
The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBRX.
